#China #biopharmaceuticals #Chengdu #Kelun-Biotech #Stock Market

Kelun-Biotech: A New Era of Growth and Innovation

On April 9, 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced a significant achievement in its developmental journey. The Hong Kong Stock Exchange (HKEX) has granted approval for the removal of the 'B' marker from its stock code, effective from April 14, 2026. This notable change symbolizes a crucial evolution in the company's standing, reflecting its commitment to meeting high industry standards in its operations.

The removal of the 'B' marker indicates that Kelun-Biotech has satisfied the relevant requirements of the Listing Rules and is now recognized for its enhanced operational capabilities. According to Dr. Michael Ge, CEO of Kelun-Biotech, this milestone underscores the company’s progress in biopharmaceutical innovation and highlights its potential for value realization within the industry.

Bridging Drug Development and Market Needs

As it stands, Kelun-Biotech has made significant strides since its initial public offering. The company has accelerated its product approvals, securing the regulatory go-ahead for four products targeting eight different medical indications within just three years of being listed. Among these, three products have been added to China’s National Reimbursement Drug List (NRDL), which showcases the firm’s integrated approach—from research and development to commercialization.

The company’s focus on addressing unmet medical needs, particularly in oncology and other major disease areas, is a testament to its commitment to advancing healthcare solutions. With a robust drug development platform, Kelun-Biotech is poised to further expand its pipeline, ultimately aiming to bridge the gap between innovative drug development and market needs.

Expanding Global Collaborations

In addition to enhancing its drug development processes, Kelun-Biotech is actively fostering global partnerships. Collaborations with prominent pharmaceutical firms such as MSD and Crescent Biopharma are instrumental in their strategy to broaden their global reach. One standout example is the advancement of the global development of sacituzumab tirumotecan (sac-TMT, 佳泰莱®), which is currently undergoing 17 global Phase III clinical trials. The expectation that multiple studies are nearing data readouts signifies the promising progress of these collaborations.

“Through these partnerships, we are not only increasing the pace of our product offerings but also enhancing our competitiveness on a global scale,” Dr. Ge added.

Innovating for the Future

In the biopharmaceutical landscape, innovation is key to sustaining growth. Kelun-Biotech is transitioning from best-in-class (BIC) innovations to first-in-class (FIC) candidates. Utilizing its state-of-the-art technology platforms in Antibody-Drug Conjugates (ADC), novel conjugation drugs, biologics, and small molecules, the company is constructing a pipeline brimming with differentiated assets.

Sac-TMT stands out as a prime example of this innovative spirit, showcasing strong competitiveness both domestically and internationally. Kelun-Biotech is now advancing several potential FIC candidates that incorporate new targets and mechanisms, thereby continually pushing the boundaries of original innovation.

With its sights set firmly on long-term sustainable development, Kelun-Biotech is committed to both enriching its portfolio and ensuring the delivery of impactful health solutions.

As Kelun-Biotech ushers in this remarkable phase of growth, it remains dedicated to expanding its innovative pipeline, fostering beneficial collaborations, and ultimately improving patient outcomes across the globe. This upcoming chapter promises not just innovation and expansion but also a strong commitment to creating long-term value for its shareholders and enhancing the well-being of patients worldwide.

To learn more about Kelun-Biotech and its extensive portfolio of innovative drugs, visit Kelun-Biotech's website.